Aug 25 (Reuters) - Genetic Signatures Ltd (GSS) :
- INFLUENZA B DETECTION EXPECTED TO IMPACT ON QUARTER SALES
- A UNDERTAKEN AN INVESTIGATION
- WELL-ADVANCED IN RESOLVING THE ISSUE, WHICH IS SPECIFIC TO INFLUENZA B VIRUS
- FOUND SEASON'S INFLUENZA B VIRUS IS NOT BEING CONSISTENTLY DETECTED IN A SMALL PROPORTION OF LOW VIRAL CONCENTRATION SAMPLES
- AT THIS TIME, WE EXPECT FORECAST REVENUE TO BE ABOUT A$2 MILLION FOR Q1 FY2023
- DETECTION OF INFLUENZA A VIRUS IS UNAFFECTED.
- IN INTERIM, SALE OF GENETIC SIGNATURES EASYSCREEN™ RESPIRATORY PATHOGEN DETECTION KIT HAS BEEN IMPACTED DURING THIS CURRENT QUARTER
News: GSS Genetic Signatures Says Influenza B Detection Expected To Impact On Quarter Sales
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
-0.010(3.77%) |
Mkt cap ! $57.92M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 25.5¢ | $41.50K | 161.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 65000 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 20000 | 1 |
View Market Depth
| Last trade - 14.51pm 18/09/2025 (20 minute delay) ? |
| GSS (ASX) Chart |